Serina Therapeutics, Inc. (SER) stock
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.09 (-6.00%)
Close on Nov 12, 2026Market cap $35.81MP/E –Yield –
Serina Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Serina Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was -$23.92M. For fiscal 2025 it was -$23.92M. The highest annual figure on record is -$3.04M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.92M | – |
| FY2024 | Dec 31, 2024 | -$16.95M | – |
| FY2023 | Dec 31, 2023 | -$3.04M | – |
| FY2020 | Dec 31, 2020 | -$9.40M | – |
| FY2019 | Dec 31, 2019 | -$12.17M | – |
| FY2018 | Dec 31, 2018 | -$11.19M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$7.84M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.75M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.59M | -2361.9% |
| Q3 FY2024 | Sep 30, 2024 | -$5.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.81M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.30M | – |
| Q4 FY2023 | Dec 31, 2023 | $247.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$928.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$949.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.96M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.31M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.17M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.78M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.16M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.11M | – |
See a number that looks wrong?